

Comparing anti-epileptic treatments for seizures following traumatic brain injury

Submission date 19/10/2020	Recruitment status No longer recruiting	☒ Prospectively registered ☐ Protocol
Registration date 20/10/2020	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 24/02/2026	Condition category Nervous System Diseases	☐ Individual participant data ☒ Record updated in last year

Plain English summary of protocol

Background and study aims

The majority of patients who suffer a traumatic brain injury (TBI) do not need to stay in hospital overnight. However, some require admission to a specialist hospital, as their injury is more serious. Seizures can be harmful or even fatal, if not treated appropriately. Medications that reduce the risk of seizures are called anti-epileptic drugs (AEDs). However, AEDs have side effects, which can affect patients' quality of life, memory, concentration and general health. Patients with seizures after TBI are typically prescribed an AED to prevent further seizures, most commonly phenytoin or levetiracetam. Some doctors favour a short course, whereas others favour a longer course. The first part of the study aims to answer if one approach is better than the other (MAST-DURATION). The second part of the study aims to answer if a 7-day course of either phenytoin or levetiracetam should be used for patients with a serious TBI to prevent seizures from happening (MAST- PROPHYLAXIS).

Who can participate?

MAST-DURATION:

Patients aged 10 and over, with a traumatic brain injury, managed in a neurosurgical unit, who have started on phenytoin or levetiracetam due to an acute symptomatic seizure during acute hospitalisation.

MAST-PROPHYLAXIS:

Patients aged 10 and over, with a traumatic brain injury, managed in a neurosurgical unit, without an acute symptomatic seizure.

What does the study involve?

MAST-DURATION:

Patients will be randomly allocated to receive to a maximum of 3 months or a minimum of 6 months course of phenytoin or levetiracetam.

MAST-PROPHYLAXIS:

Patients will be randomly allocated to receive either phenytoin, levetiracetam or no anti-epileptic drug for a period of 7 days.

Current international guidelines for traumatic brain injury recommend the use of phenytoin for the prevention of early post-traumatic seizures, when the benefits are thought to outweigh the risks. In practice, alternative anti-epileptic drugs such as levetiracetam are being used clinically

as they are associated with fewer risks.

Patients will be assessed for seizures during hospital admission and will also be asked to complete follow-up questionnaires at 6, 12, 18 and 24 months.

What are the possible benefits and risks of participating?

MAST-DURATION:

The study drugs patients will be provided with are standard anti-epileptic drugs, used to control seizures. The researchers expect seizures to be reduced as a result of taking the study drug.

MAST-PROPHYLAXIS:

There is no guarantee that patients will benefit from taking part in this trial.

Apart from the potential side effects from the study drugs, there are no additional risks or disadvantages involved with taking part in this study. Patients will continue to receive the standard care for their condition.

Where is the study run from?

Addenbrookes Hospital (UK)

When is the study starting and how long is it expected to run for?

January 2020 to May 2026

Who is funding the study?

National Institute for Health Research (NIHR) (UK)

Who is the main contact?

1. Prof. Peter Hutchinson

pjah2@cam.ac.uk

2. Dr Paula Kareclas

paula.kareclas1@nhs.net

Contact information

Type(s)

Scientific

Contact name

Prof Peter Hutchinson

ORCID ID

<https://orcid.org/0000-0002-2796-1835>

Contact details

Clinical Neurosciences, Box 167, Hills Road

Cambridge Biomedical Campus

Cambridge

United Kingdom

CB2 0QQ

+44 (0)1223 336946

pjah2@cam.ac.uk

Type(s)

Public

Contact name

Dr Paula Kareclas

ORCID ID

<https://orcid.org/0000-0002-9666-3444>

Contact details

Cambridge Clinical Trials Unit
Box 401 Addenbrookes Hospital
Hills Road
Cambridge
United Kingdom
CB2 0QQ
+44 (0)1223 596473
paula.kareclas1@nhs.net

Additional identifiers**ClinicalTrials.gov (NCT)**

NCT04573803

Clinical Trials Information System (CTIS)

2020-000282-16

Integrated Research Application System (IRAS)

276415

National Institute for Health and Care Research (NIHR)

HTA - NIHR128226

Protocol serial number

CCTU0235

Clinical trial authorisation number

CTA 24551/0044/001-0001

Study information**Scientific Title**

Pharmacological management of seizures post traumatic brain injury (MAST trial)

Acronym

MAST

Study objectives

MAST-DURATION: There will be a significant difference in the rate of late post-traumatic seizures (PTS) within 24 months post-traumatic brain injury between a longer course of phenytoin or levetiracetam (at least 6 months) and a shorter course (up to 3 months) in traumatic brain injury patients with early seizures.

MAST-PROPHYLAXIS: There will be a significant difference in the rate of post-traumatic seizures within the first 2 weeks post-traumatic brain injury between a 7-day course of phenytoin, levetiracetam or no anti-epileptic drug.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 11/01/2021, Cambridge East (East of England - Cambridge East Research Ethics Committee, The Fulbourn Centre, Home End, Fulbourn, Cambridgeshire, CB21 5BS, UK; +44 (0) 207 104 8102; cambridgeeast.rec@hra.nhs.uk), ref: 20/EE/0252

Primary study design

Interventional

Study design

MAST-DURATION: Phase III randomized multicentre pragmatic parallel-group trial
MAST-PROPHYLAXIS: Phase III randomized multicentre pragmatic parallel-group trial

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Post-traumatic seizures in traumatic brain injury patients

Interventions

MAST-DURATION: Patients will be randomized 1:1 to a maximum of 3 months OR a minimum of 6 months duration of a clinically prescribed AED (phenytoin or levetiracetam).

MAST-PROPHYLAXIS: Patients will be randomized 1:1:1 to phenytoin, levetiracetam or no AED for a period of 7 days.

Dosing for both parts of the trial will be as clinically prescribed and administered as per routine practice.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Phenytoin, levetiracetam

Primary outcome(s)

MAST-DURATION: Occurrence of late PTS measured using self-report questionnaire within 24 months after TBI

MAST-PROPHYLAXIS: Occurrence of PTS measured using clinical observation/self-report questionnaire within 2 weeks after TBI

Key secondary outcome(s)

1. Occurrence of PTS measured using self-report questionnaire up to 2 years (MAST-PROPHYLAXIS only)
2. Levels of disability measured using Extended Glasgow Outcome Scale at 6, 12, 18 and 24 months
3. Cognitive function measured using Neurobehavioural Symptom Inventory at 6, 12, 18 and 24 months
4. Quality of life measured using EQ-5D-5L at 6, 12, 18 and 24 months
5. Adverse events measured using Liverpool Adverse Events Profile at 6, 12, 18 and 24 months
6. Economic evaluation using the EQ-5D-5L questionnaire at 6, 12, 18 and 24 months
7. Frequency of PTS measured using self-report questionnaire within 24 months post traumatic brain injury
8. Mortality measured using data from the Spine for patients in England, nurse telephone calls outside England at 6, 12, 18 and 24 months
9. Adverse events of special interest measured using reports from sites and self-report during treatment

Completion date

31/05/2026

Eligibility**Key inclusion criteria****MAST-DURATION:**

1. Patients aged ≥ 10 years with TBI managed in an NSU who have started on phenytoin or levetiracetam due to an acute symptomatic seizure during acute hospitalisation
2. Patient or Legal Representative is willing and able to provide informed consent or in the absence of a legal representative, an Independent Healthcare Professional provides authorisation for patient enrolment

MAST-PROPHYLAXIS:

1. Patients aged ≥ 10 years, with TBI managed in an NSU without an acute symptomatic seizure
2. Patient or Legal Representative is willing and able to provide informed consent or in the absence of a legal representative, an Independent Healthcare Professional provides authorisation for patient enrolment

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

10 Years

Upper age limit

100 Years

Sex

All

Total final enrolment

0

Key exclusion criteria**MAST-DURATION:**

1. Un-survivable injury
2. Previous history of epilepsy
3. Patients who are on an AED pre-TBI
4. Patient who has been clinically prescribed an AED to treat PTS (other than phenytoin or levetiracetam) since current admission
5. Any hypersensitivity to study drug selected or any of its excipients

MAST-PROPHYLAXIS:

1. Post-traumatic seizures
2. Unsurvivable injury
3. Previous history of epilepsy
4. Patients who are on an AED pre-TBI
5. Pregnancy or breastfeeding
6. Any hypersensitivity to study drug (or hydantoins or pyrrolidone derivatives) or any of its excipients
7. Time interval from the time of admission to NSU to randomisation exceeds 48 hours

Date of first enrolment

05/03/2021

Date of final enrolment

31/05/2026

Locations**Countries of recruitment**

United Kingdom

England

Northern Ireland

Scotland

Wales

Study participating centre**Addenbrookes Hospital**

Cambridge University Hospitals NHS Foundation Trust
Hills Road
Cambridge

England
CB2 0QQ

Study participating centre

Freeman Hospital

Freeman Road
High Heaton
Newcastle Upon Tyne
England
NE7 7DN

Study participating centre

Derriford Hospital

Derriford Road
Plymouth
England
PL6 8DH

Study participating centre

Royal Preston Hospital

Sharoe Green Lane
Fulwood
Preston
England
PR2 9HT

Study participating centre

Southampton General Hospital

Tremona Road
Southampton
England
SO16 6YD

Study participating centre

Queen Elizabeth Hospital

Mindelsohn Way
Edgbaston
Birmingham
England
B15 2GW

Study participating centre
Walsgrave General Hospital
Clifford Bridge Road
Coventry
England
CV2 2DX

Study participating centre
Queens Medical Centre
Derby Road
Nottingham
England
NG7 2UH

Study participating centre
St. Mary's Hospital
The Bays
South Wharf Road
London
England
W2 1BL

Study participating centre
James Cook University Hospital
Marton Road
Middlesbrough
England
TS4 3BW

Study participating centre
Northern General Hospital
Herries Road
Sheffield
England
S5 7AU

Study participating centre
University Hospital Aintree
Lower Lane

Liverpool
England
L9 7AL

Study participating centre
St. James's University Hospital
Beckett Street
Leeds
England
LS9 7TF

Study participating centre
Royal Sussex County Hospital
Eastern Road
Brighton
England
BN2 5BE

Study participating centre
NHS Grampian
Summerfield House
2 Eday Road
Aberdeen
Scotland
AB15 6RE

Study participating centre
NHS Lothian
Waverley Gate
2-4 Waterloo Place
Edinburgh
Scotland
EH1 3EG

Study participating centre
NHS Greater Glasgow and Clyde
1055 Great Western Road
Glasgow
Scotland
G12 0XH

Study participating centre

Southmead Hospital

Southmead Road
Westbury-On-Trym
Bristol
England
BS10 5NB

Study participating centre

Cardiff & Vale University LHB

Heath Park
Cardiff
Wales
CF14 4XW

Study participating centre

St George's Hospital

Blackshaw Road
Tooting
London
England
SW17 0QT

Study participating centre

The Royal London Hospital

Whitechapel
London
England
E1 1BB

Study participating centre

Hull Royal Infirmary

Anlaby Road
Hull
England
HU3 2JZ

Study participating centre

NHS Tayside

Kings Croos
Cleington Road
Dundee
Scotland
DD3 8EA

Study participating centre**Salford Royal**

Stott Lane
Salford
England
M6 8HD

Study participating centre**University Hospitals of North Midlands NHS Trust**

Newcastle Road
Stoke-On-Trent
England
ST4 6QG

Study participating centre**King's College Hospital**

Denmark Hill
London
England
SE5 9RS

Study participating centre**John Radcliffe Hospital**

Headley Way
Headington
Oxford
England
OX3 9DU

Study participating centre**Queens Hospital**

Rom Valley Way

Romford
England
RM7 0AG

Study participating centre
Belfast City Hospital
Lisburn Road
Belfast
Northern Ireland
BT9 7AB

Sponsor information

Organisation
Cambridge University Hospitals NHS Foundation Trust

Organisation
University of Cambridge

Funder(s)

Funder type
Government

Funder Name
National Institute for Health Research

Alternative Name(s)
National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			26/07/2023	No	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes